Suggested treatment algorithm. At the time of first diagnosis, most patients with AHA have active bleeding that requires hemostatic therapy. Once bleeding is under control, emicizumab prophylaxis should be considered to reduce the risk of bleed relapse and subsequent bleeding. Patients who are fit for IST should be offered first-line glucocorticoids (GCs), cyclophosphamide (Cy), and/or rituximab (Ri) (see text for details). Mycophenolate mofetil (MMF) is a second-line option. Patients who are not fit for IST should be reassessed in regular intervals and considered to be receive bleed prophylaxis with emicizumab. *Note: emicizumab is currently not licensed for AHA, except in Japan.